Design and Synthesis of (3‐Phenylisoxazol‐5‐yl)methanimine Derivatives as Hepatitis B Virus Inhibitors

Series of (3‐phenylisoxazol‐5‐yl)methanimine derivatives were synthesized, and evaluated for anti‐hepatitis B virus (HBV) activity in vitro. Half of them more effectively inhibited HBsAg than 3TC, and more favor to inhibit secretion of HBeAg than to HBsAg. Part of the compounds with significant inhibition on HBeAg were also effectively inhibit replication of HBV DNA. Compound (E)‐3‐(4‐fluorophenyl)‐5‐((2‐phenylhydrazineylidene)methyl)isoxazole inhibited excellently HBeAg with IC50 in 0.65 μM (3TC(Lamivudine) in 189.90 μM), inhibited HBV DNA in 20.52 μM (3TC in 26.23 μM). Structures of compounds were determined by NMR and HRMS methods, and chlorination on phenyl ring of phenylisoxazol‐5‐yl was confirmed by X‐ray diffraction analysis, and the structure–activity relationships (SARs) of the derivatives was discussed. This work provided a new class of potent non‐nucleoside anti‐HBV agents.

[1]  Yun-Jing Huang,et al.  Discovery and biological evaluation of 2-((3-phenylisoxazol-5-yl) methoxy) benzamide derivatives as potent nucleocapsid inhibitors , 2022, Journal of Molecular Structure.

[2]  R. Saini,et al.  Design, Synthesis, and Antimicrobial Activity of Novel Isoxazolyl Imidazo[2,1‐ b ]Thiazole Libraries , 2022, Journal of Heterocyclic Chemistry.

[3]  Yun-Jing Huang,et al.  Design, synthesis, and biological evaluation of novel (E)-1-arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime derivatives as potent non-nucleoside HBV inhibitors , 2022, Journal of Molecular Structure.

[4]  R. W. Sabnis.  Combination Therapy of RNA Interference and Small Molecules for Treating Hepatitis B Virus Infection. , 2021, ACS Medicinal Chemistry Letters.

[5]  P. Zhan,et al.  Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. , 2020, European journal of medicinal chemistry.

[6]  P. Zhan,et al.  Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. , 2020, European journal of medicinal chemistry.

[7]  J. Kao,et al.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy , 2020, Clinical Microbiology Reviews.

[8]  Zhiyong Ma,et al.  Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response , 2019, Front. Immunol..

[9]  A. Siddiqui,et al.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies , 2019, Journal of Virology.

[10]  Jinhong Chang,et al.  Virological Basis for the Cure of Chronic Hepatitis B. , 2018, ACS infectious diseases.

[11]  R. Flisiak,et al.  siRNA drug development against hepatitis B virus infection , 2018, Expert opinion on biological therapy.

[12]  T. Asselah,et al.  Towards HBV curative therapies , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[13]  D. Tang,et al.  Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors. , 2018, European journal of medicinal chemistry.

[14]  P. Zhan,et al.  Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. , 2017, European journal of medicinal chemistry.

[15]  S. Raja,et al.  ISOXAZOLE – A POTENT PHARMACOPHORE , 2017 .

[16]  S. Yan,et al.  Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. , 2017, Journal of medicinal chemistry.

[17]  M. Levrero,et al.  Aiming for cure in HBV and HDV infection. , 2016, Journal of hepatology.

[18]  Kuiwu Wang,et al.  Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives. , 2016, Chemico-biological interactions.

[19]  F. Zoulim,et al.  New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. , 2016, Journal of hepatology.

[20]  J. Kao,et al.  Hepatitis B virus: new therapeutic perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[21]  Wanxing Wei,et al.  Design, synthesis, biological evaluation and molecular docking studies of phenylpropanoid derivatives as potent anti-hepatitis B virus agents. , 2015, European journal of medicinal chemistry.

[22]  F. Nan,et al.  Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation , 2014, Acta Pharmacologica Sinica.

[23]  R. Gish,et al.  Chronic hepatitis B: what should be the goal for new therapies? , 2013, Antiviral research.

[24]  D. Milich,et al.  Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection , 2003, Hepatology.

[25]  G. Papatheodoridis,et al.  Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance , 2002, American Journal of Gastroenterology.